10 annotations
driven by growth in both BD Core and BD MAX reagents with increased utilization across our larger install bas
.
Transcript
2022 Q2
3 Aug 22
recent acquisitions of Tepha and Tissuemed.
.
Transcript
2022 Q2
3 Aug 22
Farm systems' revenue grew 12.2% driven by continued strong demand for prefill devices supported by our differentiated and expanding supply capacity. Demand for these devices continues to be aided by the fast-paced vial to pre-filled device conversion for biologics, vaccines and other injectable drugs.
.
Transcript
2022 Q2
3 Aug 22
COVID only testing revenues were $214 million, which is expected to decline from $474 million last year
.
Transcript
2022 Q2
3 Aug 22
BD Libertas a pre-filled wearable injector that enables simple self-administration of larger volume doses for chronic disease
.
Transcript
2022 Q2
3 Aug 22
new BD Horizon RealYellow 586 flow psychometry reagents are the first in the series and they have the potential to Excel discovery and drug development by enabling greater insights from biological samples
.
Transcript
2022 Q2
3 Aug 22
The conflict in Ukraine, increased supply chain challenges, energy price escalation, increased inflation in COVID-driven shutdowns in China
.
Transcript
2022 Q2
3 Aug 22
BD 2025 strategy, we are reducing complexity and driving excellence across supply chain operations, which delivers efficiencies and enhances our margin profile while improving customer satisfaction. And we're doing this by improving asset utilization and labor productivity while also enhancing our supply chain resilience, responsiveness and sustainability, all of which are more critical than ever in today's environment.
.
Transcript
2022 Q2
3 Aug 22
we are fuelling our growth strategy with investments in organic innovation and tuck-in M&A
.
Transcript
2022 Q2
3 Aug 22
BD 2025 strategy
.
Transcript
2022 Q2
3 Aug 22
- Prev
- 1
- Next